00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:22 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 patients in the third cohort of Part A of Phase II ACHIEVE trial to treat chronic HBV infection showing that 100 mg inarigivir soproxil led to...
21:08 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

A grand jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics Ltd. (ASX:IIL) by alerting family members of a clinical trial failure before the results were made...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Spring Bank reports Phase II data for HBV candidate

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 treatment-naive patients with chronic HBV infection without cirrhosis in the first cohort of the Phase II ACHIEVE trial showing that once-daily 25 mg inarigivir soproxil (formerly...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
18:45 , Jul 21, 2017 |  BC Week In Review  |  Company News

Spring Bank and Gilead combo trial to treat chronic HBV

Gilead Sciences Inc. (NASDAQ:GILD) will fund and conduct a Phase II evaluating its HBV drug Vemlidy tenofovir alafenamide fumarate plus SB 9200 from Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) in patients with chronic HBV infection. Spring...
20:06 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Innate's MIS416 fails in Phase IIb for MS

Innate Immunotherapeutics Ltd. (ASX:IIL) reported top-line data from a double-blind, Australian and New Zealand Phase IIb trial in 93 patients with secondary progressive multiple sclerosis (MS) showing that once-weekly 500 μg IV MIS416 for 52...
23:29 , Jun 22, 2017 |  BC Extra  |  Financial News

Spring Bank raises $37.5M follow-on

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) raised $37.5 million through the sale of 2.9 million shares at $13 in a follow-on underwritten by Cantor Fitzgerald, William Blair and Chardan. The price is a 6% discount to...
20:24 , May 26, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of Phase II for SB 9200 in HBV

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) said an independent DSMB recommended continuation of the Phase II ACHIEVE trial evaluating SB 9200 in treatment-naïve HBV patients without cirrhosis. The company has begun enrollment in the second cohort...